Stefano Provera
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stefano Provera.
Magnetic Resonance in Chemistry | 2010
Roger D. Farrant; John C. Hollerton; Sean M. Lynn; Stefano Provera; Philip J. Sidebottom; Richard J. Upton
We have developed QUANTAS (QUANTification by Artificial Signal), which is a software‐based protocol for concentration measurement by NMR. QUANTAS is an absolute intensity external standard method for quantification by NMR that compensates for various experimental parameters. It is applicable to all nuclei and modern spectrometers. QUANTAS is demonstrated here for 1H and 19F NMR, enabling heteronuclear integrals to be compared. It can be applied using fixed probe tuning, matching and pulse length, for samples with the same effective loading on the probe coil as the appropriate reference spectrum. Otherwise, an optimised tuning and matching approach is adopted for every sample together with explicit PULCON (PUlse Length‐based CONcentration measurements) absolute intensity corrections. Copyright
Journal of Medicinal Chemistry | 2008
Daniele Simoni; Nicola Gebbia; Francesco Paolo Invidiata; Marco Eleopra; Paolo Marchetti; Riccardo Rondanin; Riccardo Baruchello; Stefano Provera; Carla Marchioro; Manlio Tolomeo; Luciana Marinelli; Vittorio Limongelli; Ettore Novellino; Aaron Kwaasi; J E Dunford; Simona Buccheri; Nadia Caccamo; Francesco Dieli
A small series of aminobisphosphonates (N-BPs) structurally related to zoledronic acid was synthesized with the aim of improving activity toward activation of human gammadelta T cells and in turn their in vivo antitumor activity. The absence of the 1-OH moiety, together with the position and the different basicity of the nitrogen, appears crucial for antitumor activity. In comparison to zoledronic acid, compound 6a shows a greater ability to activate gammadelta T cells expression (100 times more) and a proapoptotic effect that is better than zoledronic acid. The potent activation of gammadelta T cells, in addition to evidence of the in vivo antitumor activity of 6a, suggests it may be a new potential drug candidate for cancer treatment.
Journal of Medicinal Chemistry | 2009
Romano Di Fabio; Cristiana Griffante; Giuseppe Alvaro; Giorgio Pentassuglia; Domenica Antonia Pizzi; Daniele Donati; Tino Rossi; Giuseppe Guercio; Mario Mattioli; Zadeo Cimarosti; Carla Marchioro; Stefano Provera; Laura Zonzini; Dino Montanari; Sergio Melotto; Philip Gerrard; David G. Trist; Emiliangelo Ratti; Mauro Corsi
In an effort to discover novel druglike NK(1) receptor antagonists a new series of suitably substituted C-phenylpiperazine derivatives was identified by an appropriate chemical exploration of related N-phenylpiperazine analogues, with the specific aim to maximize their in vitro affinity and optimize in parallel their pharmacokinetic profile. Among the compounds synthesized, 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) was identified as one of the most in vitro potent and selective NK(1) receptor antagonists ever discovered, showing appropriate pharmacokinetic properties and in vivo activity. On the basis of its preclinical profile, this compound was selected as a drug candidate.
Journal of Medicinal Chemistry | 2008
Romano Di Fabio; Yves St-Denis; Fabio Maria Sabbatini; Daniele Andreotti; Roberto Arban; Giovanni Bernasconi; Simone Braggio; Frank E. Blaney; Anna Maria Capelli; Emiliano Castiglioni; Enza Di Modugno; Daniele Donati; Elettra Fazzolari; Emiliangelo Ratti; Aldo Feriani; Stefania Contini; Gabriella Gentile; Damiano Ghirlanda; Stefano Provera; Carla Marchioro; Karen Roberts; Anna Mingardi; Mario Mattioli; Arnaldo Nalin; Francesca Pavone; Simone Spada; David G. Trist; Angela Worby
To identify new CRF(1) receptor antagonists, an attempt to modify the bis-heterocycle moiety present in the top region of the dihydropyrrole[2,3]pyridine template was made following new pharmacophoric hypothesis on the CRF(1) receptor antagonists binding pocket. In particular, the 2-thiazole ring, present in the previous series of compounds, was replaced by more hydrophilic non aromatic heterocycles able to make appropriate H-bond interactions with amino acid residues Thr192 and Tyr195. This exploration, followed by an accurate analysis of the substitution of the pendant aryl ring, enabled to identify in vitro potent compounds showing excellent pharmacokinetics and outstanding in vivo activity in animal models of anxiety, both in rodents and primates.
Tetrahedron Letters | 2002
Elena La Porta; Umberto Piarulli; Francesca Cardullo; Alfredo Paio; Stefano Provera; Pierfausto Seneci; Cesare Gennari
A new synthesis of macrolactones bearing a cyclopropyl ring condensed to the macrocycle is reported via a cyclization-release strategy making use of solid-phase supported stabilized sulfur ylides.
Journal of Medicinal Chemistry | 2011
Romano Di Fabio; Giuseppe Alvaro; Cristiana Griffante; Domenica Antonia Pizzi; Daniele Donati; Mario Mattioli; Zadeo Cimarosti; Giuseppe Guercio; Carla Marchioro; Stefano Provera; Laura Zonzini; Dino Montanari; Sergio Melotto; Philip Gerrard; David G. Trist; Emiliangelo Ratti; Mauro Corsi
A large body of compelling preclinical evidence supports the clinical use of neurokinin (NK) receptor antagonists in a plethora of CNS and non-CNS therapeutic areas. The significant investment made in this area over the past 2 decades culminated with the observation that NK(1) receptor antagonists elicited clinical efficacy in major depression disorders. In addition, aprepitant (Merck) was launched as a new drug able to prevent chemotherapy-induced nausea and vomiting (CINV). After the discovery by GlaxoSmithKline of vestipitant, a wide drug discovery program was launched aimed at identifying additional clinical candidates. New compounds were designed to maximize affinity at the NK(1) receptor binding site while retaining suitable physicochemical characteristics to ensure excellent pharmacokinetic and pharmacodynamic properties in vivo. Herein we describe the discovery process of a new NK(1) receptor antagonist (casopitant) selected as clinical candidate and progressed into clinical studies to treat major depression disorders.
Farmaco | 2002
M Dal Cin; Silvia Davalli; Carla Marchioro; M Passarini; O Perini; Stefano Provera; A Zaramella
Solid phase synthesis (SPS) is a powerful technique to assemble compound libraries in high-throughput parallel and combinatorial synthesis. The widespread applications of these techniques required the development of analytical methods for both structural elucidation and reaction monitoring. This review covers some recently developed techniques for on-bead analyses together with solution-state ones. Particular emphasis is devoted to software and hardware improvements for automated high-throughput analysis.
Journal of Medicinal Chemistry | 2010
Fabrizio Micheli; Luca Arista; Barbara Bertani; Simone Braggio; Anna Maria Capelli; Susanna Cremonesi; Romano Di-Fabio; Giacomo Gelardi; Gabriella Gentile; Carla Marchioro; Alessandra Pasquarello; Stefano Provera; Giovanna Tedesco; Luca Tarsi; Silvia Terreni; Angela Worby; Christian Heidbreder
A novel series of 1,2,4-triazol-3-yl-azabicyclo[3.1.0]hexanes with high affinity and selectivity for the DA D(3) receptor and excellent pharmacokinetic profiles was recently reported. We also recently discussed the role of the linker associated with the triazole moiety. In this manuscript, we are reporting a detailed exploration of the region of the receptor interacting with the amine terminus of the scaffold wherein SAR and developability data associated with these novel templates was undertaken.
Tetrahedron Letters | 2000
Stefano Maiorana; Clara Baldoli; Emanuela Licandro; Laura Casiraghi; Elisabetta de Magistris; Alfredo Paio; Stefano Provera; Pierfausto Seneci
New fluorobenzene chromium dicarbonylisocyanide complexes have been synthesized and evaluated in terms of their ‘in solution’ reactivity towards some nucleophiles. For the first time the polymer-bound isocyanides have been found to be valuable ligands for anchoring haloareneCr(CO)3 complexes by means of their substitution for a CO group. The supported fluorobenzene complex reacted with nitrogen-nucleophiles.
Tetrahedron Letters | 1999
Stefano Maiorana; Pierfausto Seneci; Tino Rossi; Clara Baldoli; Manuela Ciraco; Elisabetta de Magistris; Emanuela Licandro; Antonio Papagni; Stefano Provera
Abstract A series of polymer-bound Fischer chromium alkoxy and amino carbene type I complexes were synthesized by the thermal exchange of a CO ligand in chromium pentacarbonyl carbenes 2 with triphenyl phosphine resin 1 . The supported alkoxycarbene 3a proved to be reactive towards primary amines, and afforded the polymer-bound aminocarbenes 5 . Type II aminocarbenes were also prepared by reacting polymer-supported aminoacids with alkoxycarbene 2a .